Thank you for visiting the June 2024 Partners' Blog! I hope that you find the featured information helpful.
The Corporate Affiliates Program provides an exciting opportunity for companies to support the work of the American Society of Transplantation (AST) and receive tangible benefits throughout the year. The following companies are members of the 2024 Corporate Affiliate Program (CAP).
For additional partner information, check out AST Partner Connect.
Alex Wiseman
AST Development Chair
Bridge to Life Ltd. is a market leader in organ preservation solutions and medical technologies, offering premier products such as Belzer UW, EasiSlush and the VitaSmart Machine Perfusion System. With a strong focus on product quality, innovation and accessibility, Bridge to Life is at the forefront of forging meaningful and productive academia and transplantation industry partnerships and collaborations that will advance the critical research initiatives necessary to improve organ availability and accessibility.
Advancing Organ Preservation with the Bridge to HOPE Trial
A significant stride in their mission is the ongoing pivotal randomized multi-center Bridge to HOPE clinical trial in the U.S. This unique trial investigates the efficacy of hypothermic oxygenated perfusion (HOPE) in preserving livers for transplantation and aims to evaluate the clinical safety and efficacy of the current standard, static cold storage (SCS), against SCS followed by HOPE using the VitaSmart Machine Perfusion System. HOPE, already utilized in more than a dozen countries, involves cooling organs to 4-10°C, which reduces their metabolic rate to about 10% of normal. This process rejuvenates the mitochondria, the cells' powerhouses, preparing them for transplantation and potentially minimizing reperfusion injury post-surgery. While enrollment in the pivotal 15 center study has been completed, the company is in the final month of collecting one year patient follow-up data which it then expects to submit to the FDA later this year.
This trial could redefine the standards for ex-vivo organ preservation, paving the way for broader adoption of advanced preservation techniques.
Addressing the Urgent Need for Improving Organ Preservation and Utilization
With the growing number of candidates on transplant waiting lists and a global shortage of suitable donors, there is a pressing need to understand the biological mechanisms behind transplantation better. Bridge to Life is at the forefront of this research, focusing on mitochondrial studies to tackle inflammation, a key factor in organ dysfunction and recipient complications. This research aims to increase the number of organs available for transplantation, ultimately saving more lives.
Promising Clinical Data and Global Impact
Currently, HOPE is available only outside the U.S., but accumulating clinical data suggest its outcomes are comparable or even superior to normothermic systems. The VitaSmart system's simplicity has garnered widespread acclaim for its ease of use, minimal monitoring requirements, and cost-effectiveness.
Bridge to Life Ltd. continues to lead the charge in organ preservation innovation, combining product excellence with strategic research partnerships. Through trials like Bridge to HOPE, they are not only improving transplantation outcomes but also addressing the critical shortage of viable donor organs, thereby enhancing the quality of life for countless patients worldwide. Come visit us at booth 618 the upcoming ATC meeting in Philadelphia to learn more.
Eurofins Transplant is thrilled to announce our participation in the American Transplant Congress, taking place from June 1st to 5th in Philadelphia, PA!
We have two exciting events lined up, and we would be delighted for you to join us. First up is our Symposium on June 2nd at 12:15 PM. Titled "Widening the Lens in Transplant: TruGraf, TRAC ID, and CMV inSIGHT," this symposium will feature Dr. Michael Marvin, MD, Chair of the Department of Transplantation and Liver Surgery at Geisinger Health System, and Professor of Surgery at Geisinger Commonwealth School of Medicine, along with Dr. Deepali Kumar, MD, MSC, FRCP(C), AST President, and Professor of Medicine at the University of Toronto, and Transplant and Infectious Disease Physician at University Health Network. These doctors will discuss the unique challenges of post-transplant care, immunosuppression management, and the consequences of CMV in their patient population.
Additionally, we invite you to join us for an open event, the Taste of Philly Experience, at the Uptown Beer Garden on Monday, June 3rd, starting at 7:30 PM. It's an excellent opportunity to network, enjoy refreshments, and immerse yourself in the vibrant atmosphere of Philadelphia's summertime charm.
If you're unable to attend, don’t worry! You can still catch up with us at Booth #300 throughout the conference to delve into the science behind our tests and learn more about our work.
We look forward to connecting with you in Philly!
As a proud partner of AST, Kamada is excited to exhibit at this year's ATC in Philadelphia!
Come meet us at booth #720 to discuss how you can help protect your transplant patients from post-transplant infections like CMV, HBV and VZV.
We are proud that emerging clinical data about CMV IGIV will be presented at this year's ATC meeting for the first time in many years. You are welcome to attend a poster presentation, titled Antiviral Effect of Cytomegalovirus (CMV) Immune Globulin After Liver Transplantation in Patients Who Were Not CMV Donor Positive/Recipient Negative on Tuesday, June 4, 9:15-10:00 AM ET & 2:30-3:15 PM ET at the poster hall, when Dr. Jennifer Chow, an Associate Professor at Tufts University School of Medicine, will present the center's data and conclusions.
Furthermore, we cordially invite you to the first edition of CMV Stream on June 5th at 6 PM EST.
This online event, focusing on advanced strategies for managing CMV after solid organ transplantation, will be broadcast live from Philadelphia following the conclusion of the ATC meeting. Please visit www.cmvstream.com to view the panelist lineup and secure your registration.
About Kamada: Established over three decades ago, Kamada is a global biopharmaceutical company focused on transplantation and infectious diseases. We offer a broad range of hyperimmune plasma therapies that provide passive immunity to various infectious agents.
On behalf of our team, we hope you'll have a great ATC meeting.
See you there!
Natera provides advanced DNA technology that enables transplant providers to deliver quality, personalized care. As a diagnostics company with proprietary bioinformatics and molecular technology, we’ve performed more than 10 million cfDNA tests and are dedicated to improving kidney, heart, and lung care for good. Visit us at booth #413 to learn more.
Ground-Breaking Digital Diagnostic
Redefining Precision Immunology
What is PIRCHE?
PIRCHE is a technology leader in the application of AI to molecular medicine and has developed an exclusive epitope matching technology. The technology is redefining compatibility risk assessment as this is the prerequisite for foreign tissue or cells to enter the body and be accepted by the host immune system.
Why PIRCHE?
Currently, the compatibility risk assessment is sub-optimally achieved with second-generation analysis techniques such as next-generation gene sequencing, antibody screening tools, and extensive use of pharmaceuticals, which may result in decreased longevity of organ transplantation.
As so, PIRCHE represents a third-generation tool for immune risk profiling via technology based on epitope matching with the evidence to be disruptive in the field of transplantation medicine and allogeneic cell therapies. The technology relies on clinical labs that are already standard of care.
The medical evidence is backed by more than 70 peer-reviewed publications on more than 250,000 patient cases, and has been utilized in 850 transplant centers worldwide.
How & Where To Use PIRCHE
PIRCHE’s front end product is a first and only-in-class proprietary digital diagnostic platform that enables physicians and drug developers to make informed decisions for:
1) Living & Deceased donor-recipient risk assessment
2) Management of immunosuppression regimens
3) Personalized selection of induction therapies
4) Biomarker scheduling support
Who should know about PIRCHE?
We are looking to become a partner with transplant clinicians, HLA laboratory staff, and Administrators of transplant centers. Our goal is to aid in personalizing patient care with molecular technology by improving diagnostic support services and helping to conserve center resources.
Join us at this year’s American Transplant Congress (ATC) Booth #308 and see how we’re partnering together to promote Efficiency and Equity in Transplantation!
From June 1st through 5th, help us celebrate Sanofi’s 25+ Years of Partnership with the Kidney Transplant Community.
Stop by the Sanofi booth to:
- Learn how your center can grow its transplant program and help meet the KHI and OPTN transplant goals
- Hear what we can do together to enhance living donor programs
- Discuss the use of suboptimal kidneys and current allocation pathways
- Step up to the photo booth wall and share your pictures to encourage others to #Pledge2Reflect to make a difference
Throughout Sanofi’s 25+ years of partnership with the Transplant Community, we have been dedicated to empowering healthcare providers and patients, educating the kidney transplant community, and providing innovative resources to our valued partners.
The future of transplant starts with you—the providers. As your partner in transplant, we stand proudly by your side. To learn more about our partnership with the transplant community and the resources we provide, please visit sanofi.astpartnerconnect.com.
Check out all of our CAP partners:
Advertisements
